These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35278766)

  • 21. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.
    Kubota K; Hida T; Ishikura S; Mizusawa J; Nishio M; Kawahara M; Yokoyama A; Imamura F; Takeda K; Negoro S; Harada M; Okamoto H; Yamamoto N; Shinkai T; Sakai H; Matsui K; Nakagawa K; Shibata T; Saijo N; Tamura T;
    Lancet Oncol; 2014 Jan; 15(1):106-13. PubMed ID: 24309370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer.
    Spigel DR; Greco FA; Zubkus JD; Murphy PB; Saez RA; Farley C; Yardley DA; Burris HA; Hainsworth JD
    J Thorac Oncol; 2009 Dec; 4(12):1555-60. PubMed ID: 19875975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901.
    Morikawa N; Inoue A; Sugawara S; Maemondo M; Harada T; Harada M; Fujita Y; Katoh T; Yokouchi H; Watanabe H; Usui K; Suzuki T; Sakakibara-Konishi J; Nagai H; Kanbe M; Nukiwa T
    Lung Cancer; 2017 Sep; 111():38-42. PubMed ID: 28838395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FOLFIRI in advanced platinum-resistant/refractory small-cell lung cancer: a retrospective study.
    Roussel-Simonin C; Gougis P; Lassoued D; Vozy A; Veyri M; Morardet L; Wassermann J; Foka Tichoue H; Jaffrelot L; Hassani L; Perrier A; Bergeret S; Taillade L; Spano JP; Campedel L; Abbar B
    Acta Oncol; 2023 Jun; 62(6):579-586. PubMed ID: 37276270
    [TBL] [Abstract][Full Text] [Related]  

  • 25. E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer.
    Owonikoko TK; Aisner J; Wang XV; Dahlberg SE; Rubin EH; Ramalingam SS; Gounder M; Rausch PG; Axelrod RS; Schiller JH
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):171-80. PubMed ID: 24288121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase Ib/II study on the safety, tolerability, and preliminary efficacy of pegylated irinotecan (JK1201I) as second-line monotherapy for patients with small-cell lung cancer.
    Long J; Li X; Wu L; Yu G; Zang A; Zhao Y; Shi J; Nie L; Zhao X; Fang J
    Cancer Med; 2024 Sep; 13(17):e70059. PubMed ID: 39225504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer.
    Chiappori AA; Otterson GA; Dowlati A; Traynor AM; Horn L; Owonikoko TK; Ross HJ; Hann CL; Abu Hejleh T; Nieva J; Zhao X; Schell M; Sullivan DM
    Oncologist; 2016 Oct; 21(10):1163-1164. PubMed ID: 27694157
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topotecan: a review of its efficacy in small cell lung cancer.
    Ormrod D; Spencer CM
    Drugs; 1999 Sep; 58(3):533-51. PubMed ID: 10493279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancer.
    Spigel DR; Greco FA; Burris HA; Shipley DL; Clark BL; Whorf RC; Arrowsmith ER; Hainsworth JD
    Clin Lung Cancer; 2011 May; 12(3):187-91. PubMed ID: 21663862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized phase II study of maintenance irinotecan therapy versus observation following induction chemotherapy with irinotecan and cisplatin in extensive disease small cell lung cancer.
    Han JY; Kim HT; Lim KY; Yoon SJ; Lee DH; Lee JS
    J Thorac Oncol; 2008 Sep; 3(9):1039-45. PubMed ID: 18758308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group.
    Schiller JH; Adak S; Cella D; DeVore RF; Johnson DH
    J Clin Oncol; 2001 Apr; 19(8):2114-22. PubMed ID: 11304763
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.
    Nogami N; Hotta K; Kuyama S; Kiura K; Takigawa N; Chikamori K; Shibayama T; Kishino D; Hosokawa S; Tamaoki A; Harita S; Tabata M; Ueoka H; Shinkai T; Tanimoto M
    Lung Cancer; 2011 Oct; 74(1):80-4. PubMed ID: 21334093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 Patients.
    Horita N; Yamamoto M; Sato T; Tsukahara T; Nagakura H; Tashiro K; Shibata Y; Watanabe H; Nagai K; Inoue M; Nakashima K; Ushio R; Shinkai M; Kudo M; Kaneko T
    Sci Rep; 2015 Oct; 5():15437. PubMed ID: 26486755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung cancer.
    Spigel DR; Hainsworth JD; Gandhi JG; Gian VG; Peyton JD; West-Osterfield K; Clark BL; Vazquez ER; Jones SF; Burris HA; Greco FA
    J Thorac Oncol; 2010 Jun; 5(6):862-6. PubMed ID: 20521352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer.
    Okuma HS; Horinouchi H; Kitahara S; Asao T; Sunami K; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Ohe Y
    Clin Lung Cancer; 2017 Mar; 18(2):234-240.e2. PubMed ID: 27867001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer.
    Trafalis DT; Alifieris C; Stathopoulos GP; Sitaras N
    Cancer Chemother Pharmacol; 2016 Apr; 77(4):713-22. PubMed ID: 26891956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study.
    Tomono H; Taniguchi H; Fukuda M; Ikeda T; Nagashima S; Akagi K; Ono S; Umeyama Y; Shimada M; Gyotoku H; Takemoto S; Hisamatsu Y; Morinaga R; Tagawa R; Ogata R; Dotsu Y; Senju H; Soda H; Nakatomi K; Hayashi F; Sugasaki N; Kinoshita A; Mukae H
    Thorac Cancer; 2023 Oct; 14(28):2890-2894. PubMed ID: 37675546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemo-immunotherapy with dinutuximab beta in patients with relapsed/progressive high-risk neuroblastoma: does chemotherapy backbone matter?
    Raiser P; Schleiermacher G; Gambart M; Dumont B; Defachelles AS; Thebaud E; Tandonnet J; Pasqualini C; Proust S; Entz-Werle N; Aerts I; Ndounga-Diakou LA; Petit A; Puiseux C; Khanfar C; Rouger J; Mansuy L; Benadiba J; Millot F; Pluchart C; Laghouati S; Geoerger B; Vassal G; Valteau-Couanet D; Berlanga P
    Eur J Cancer; 2024 May; 202():114001. PubMed ID: 38489858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival analysis in second-line and third-line chemotherapy with irinotecan followed by topotecan or topotecan followed by irinotecan for extensive-stage small-cell lung cancer patients: a single-center retrospective study.
    Aktas G; Kus T; Kalender ME; Sevinc A; Camci C; Kul S
    Onco Targets Ther; 2016; 9():1921-6. PubMed ID: 27099522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer.
    Choudhury NJ; Lai WV; Makhnin A; Heller G; Eng J; Li B; Preeshagul I; Santini FC; Offin M; Ng K; Paik P; Larsen C; Ginsberg MS; Lau Y; Zhang X; Baine MK; Rekhtman N; Rudin CM
    Clin Cancer Res; 2024 Sep; 30(17):3697-3703. PubMed ID: 38940666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.